PharmacoEconomics Open (2017) 1:279–290 https://doi.org/10.1007/s41669-017-0031-6 ORIGINAL RESEARCH ARTICLE Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden 1 1 1 2 • • • • Ugne Sabale Mattias Ekman Daniel Thunstro¨m Claire Telford Christopher Livings Published online: 1 June 2017 The Author(s) 2017. This article is an open access publication Abstract €33,808, €33,883, and €49,225 per QALY with incre- Objectives In Sweden, breast cancer (BC) represents 30% mental costs of €13,283, €14,986, and €13,862, and of newly diagnosed cancers and is the most common incremental QALYs of 0.393, 0.442, and 0.282, respec- cancer in women. For hormone-dependent BC, endocrine tively. Incremental cost per life-year (LY) gained €21,312 therapies varying in efﬁcacy and price are available. The (incremental LY of 0.623), €20,338 (incremental LY of aim of this study is to assess the cost effectiveness of 0.737), and €27,854 (incremental LY of 0.498) for fulvestrant 500 mg as a second-line hormonal therapy for respective comparators. Applying the upper and lower postmenopausal women with estrogen receptor-positive credible intervals for PFS/OS from the meta-analysis had metastatic or locally advanced BC versus letrozole, anas- the greatest effect on the ICER in the sensitivity
PharmacoEconomics - Open – Springer Journals
Published: Jun 1, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud